SBIR/STTR Research Award

Inhibitors of KD08-Phosphate Synthase as Antibiotics

Award identifier 33d27fae165c8c37869ca8f3aec4aaf431f80eea3f9c516ec6ade3580fb955a6Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$208,500

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CUBIST PHARMACEUTICALS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The increasing occurrence of pathogenic bacteria that are resistant to historically successful antibiotics has driven the need to develop new classes of drugs that have a unique mechanism of action. Gram-negative pathogens pose a serious health threat as they can be the causative agents of life-threatening conditions such as septicemia (Escherichia coli), meningitis (Haemophilus influenzae) or pyrogenic infections in burn patients and diabetics (Pseudomonas aeruginosa). 3-deoxy-D-manno-octulosonic-8-phosphate synthase (KDO8PS; EC 4.1.2.16) has been demonstrated to be an essential enzyme for gram-negative pathogen viability as it carries out a key step in the biosynthesis of the outer membrane lipopolysaccharide component, namely the condenstaion of phosphoenolpyruvate and arabinose-5-phosphate to form 3-deoxy-D-mann-octulosonic-8-phosphate. We propose to identify inhibitors of KDO8PS that can be further developed into antibiotics for use in treating infections by gram-negative pathogens. The specific aims are to clone and express the gene for KDO8PS from E. coli and P. aeruginosa, purify the enzyme to homogeneity, and develop assays for high throughput screening and compound characterization that can be used to identify and develop inhibitors of KDO8PS as potential antibiotics. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.